摘要
γ-氨基丁酸A型受体(GABAAR),包括其α5亚单位(α5GABAAR)主要在海马体中被发现。在海马体中,它们调停一种强直氯化物泄漏电流,在GABA能抑制性突触电流中构成减速部分。它们对海马神经元兴奋的抑制作用至少部分地解释了为什么改变α5GABAAR的活动水平会影响认识,学习和记忆。这些受体作为一些临床情况潜在的治疗靶点被涉及。这些临床情况包括老年痴呆、中风、精神分裂症、唐氏综合症和麻醉诱发的失忆。因此,一些选择性地指向 α5GABAAR的药理调节剂被作为抑制剂或变构增强剂而发展出来。虽然这些化合物中有许多展示了对上述失调症状的动物模型的治疗作用,但没有一个上市,因为临床试验的失败和人体毒性。这些实验也揭示了α5GABAAR调节的矛盾效果(如:正向和逆向调节都可以治愈认知障碍)。这说明我们对于 α5GABAAR的生理作用的认识是不完全的。这篇综述着重描述了α5GABAAR已被发展出的各种调节剂,关于它们在行为研究中的效果的重要发现,这些研究横跨多个治疗领域的重要性,以及我们对于 α5GABAAR的生理和病理作用的知识缺口。
关键词: 变构调节剂,α5GABAA受体,老年痴呆,健忘症,唐氏综合症,记忆损伤,益智药,中风。
图形摘要
Current Drug Targets
Title:Selective Modulators of α5-Containing GABAA Receptors and their Therapeutic Significance
Volume: 16 Issue: 7
Author(s): Ming Shiuan Soh and Joseph W. Lynch
Affiliation:
关键词: 变构调节剂,α5GABAA受体,老年痴呆,健忘症,唐氏综合症,记忆损伤,益智药,中风。
摘要: GABAA receptors containing the α5 subunit (α5GABAARs) are found mainly in the hippocampus where they mediate a tonic chloride leak current and contribute a slow component to GABAergic inhibitory synaptic currents. Their inhibitory effect on the excitability of hippocampal neurons at least partly explains why changes in the level of activity of α5GABAARs affect cognition, learning and memory. These receptors have been implicated as potential therapeutic targets for a range of clinical conditions including age-related dementia, stroke, schizophrenia, Down syndrome and anesthetic- induced amnesia. Accordingly, a range of pharmacological modulators that selectively target α5GABAARs, as either inhibitors or allosteric enhancers, have been developed. Although many of these compounds show therapeutic effects in animal models of the above clinical disorders, none has been marketed yet due to unsuccessful clinical trials and toxicity in humans. These experiments have also revealed paradoxical effects of α5GABAAR modulation (e.g., cognitive impairments can be reversed by both positive and negative modulation), suggesting that our knowledge of the physiological roles of α5GABAARs is incomplete. This review highlights the various positive and negative modulators for α5GABAARs that have been developed, key findings concerning their effects in behavioral studies, and their importance across a number of therapeutic fields. It also highlights some of the gaps in our knowledge of the physiological and pathological roles of α5GABAARs.
Export Options
About this article
Cite this article as:
Ming Shiuan Soh and Joseph W. Lynch , Selective Modulators of α5-Containing GABAA Receptors and their Therapeutic Significance, Current Drug Targets 2015; 16 (7) . https://dx.doi.org/10.2174/1389450116666150309120235
DOI https://dx.doi.org/10.2174/1389450116666150309120235 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vitamins Mediate Immunological Homeostasis and Diseases at the Surface of the Body
Endocrine, Metabolic & Immune Disorders - Drug Targets Co-Enzyme Q10 to Treat Neurological Disorders: Basic Mechanisms, Clinical Outcomes, and Future Research Direction
CNS & Neurological Disorders - Drug Targets Natural Products Based Ayurvedic Formulations: Chemical Cons tituents and Treatment in Neurodegenerative Disordersǂ
Mini-Reviews in Organic Chemistry Analysis of NCL Proteins from an Evolutionary Standpoint
Current Genomics Alzheimer’s Disease-related Biomarkers in Aging Adults with Down Syndrome: Systematic Review
Current Psychiatry Research and Reviews Inhibitory Mechanism of An Anticancer Drug, Bexarotene Against Amyloid β Peptide Aggregation: Repurposing Via Neuroinformatics Approach
Current Pharmaceutical Design Antioxidant Agents in Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry New Developments of Clinical Trial in Immunotherapy for Alzheimer's Disease
Current Pharmaceutical Biotechnology Gene Transfer to the Central Nervous System: Current State of the Art of the Viral Vectors
Current Genomics Meet Our Associate Editor
Central Nervous System Agents in Medicinal Chemistry Cyclooxygenase Inhibitors: Instrumental Drugs to Understand Cardiovascular Homeostasis and Arterial Thrombosis
Cardiovascular & Hematological Disorders-Drug Targets Parkinson's Disease: A Role for the Immune System
Current Molecular Pharmacology Rab GTPases, Membrane Trafficking and Diseases
Current Drug Targets Protective Effects of Polydatin Against Dementia-Related Disorders
Current Neuropharmacology Inhibition of Glycogen Synthase Kinase-3 Reverses Tau Hyperphosphorylation Induced by Pin1 Down-Regulation
CNS & Neurological Disorders - Drug Targets AβPP-induced UPR Transcriptomic Signature of Glial Cells to Oxidative Stress as an Adaptive Mechanism to Preserve Cell Function and Survival
Current Alzheimer Research Impact of Diabetes in Blood-Testis and Blood-Brain Barriers: Resemblances and Differences
Current Diabetes Reviews A Novel Prescription for Alzheimer’s Disease: Targeting Hypercoagulable States
Current Neurovascular Research The Nrf2-ARE Pathway: A Valuable Therapeutic Target for the Treatment of Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Epidemiology, Prognosis and Prevention of Non-Traumatic Intracerebral Hemorrhage
Current Pharmaceutical Design